Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA

 Savara (SVRA) has revealed that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Molbreevi, a therapeutic option aimed at treating individuals with autoimmune pulmonary alveolar proteinosis (PAP). The FDA has also assigned a Priority Review to this application, setting a target decision date under the Prescription Drug User Fee Act (PDUFA) for August 22, 2026.

https://www.gurufocus.com/news/8637850/savara-svra-gains-fda-priority-review-for-molbreevi-bla